884
P A R T 1 0
Drugs acting on the respiratory system
BIBLIOGRAPHY
Abramson, M., Glasgow, N. & McDonald, C. (2007). Managing
chronic obstructive pulmonary disease.
Australian Prescriber,
30,
64–67.
Bostock-Cox, B. (2013). Managing asthma in the community:
A guide for nursing staff.
British Journal of Community
Nursing, 18(3)
, 125–127.
Dandan, R. (2012). Indacaterol: A Once-Daily Ultra-Long Acting
β
2
Agonist for the Treatment of COPD. Access Medicine from
McGraw Hill.
Dhand, R., Dolovich, M., Chipps, B., Myer, T. R., Restrepo, R.
& Farrar, J. R. (2012). The role of nebulized therapy in the
management of COPD: Evidence and recommendations.
COPD:
Journal of Chronic Obstructive Pulmonary Disease, 9(1)
, 58–72.
Farrell, M. & Dempsey, J. (2014).
Smeltzer & Bare’s Textbook of
Medical-Surgical Nursing
(3rd edn). Sydney: Lippincott Williams
& Wilkins.
Goodman, L. S., Brunton, L. L., Chabner, B. & Knollmann, B. C.
(2011).
Goodman and Gilman’s Pharmacological Basis of
Therapeutics
(12th edn). New York: McGraw-Hill.
Jenkins, C. (2006). Starting steroids for asthma.
Australian
Prescriber
, 29, 63–66.
Lim, A., Hussainy, S. Y. & Abramson, M. J. (2013). Asthma drugs in
pregnancy and lactation.
Australian Prescriber, 36(5)
, 150–153.
McKenna, L. (2012).
Pharmacology Made Incredibly Easy
(1st Australian and New Zealand edn). Sydney: Lippincott
Williams & Wilkins.
McKenna, L. & Mirkov, S. (2014).
McKenna’s Drug Handbook for
Nursing and Midwifery
(7th edn). Sydney: Lippincott Williams
& Wilkins.
National Asthma Council Australia. (2006).
Asthma Management
Handbook 2006
. Melbourne: National Asthma Council
Australia.
Porth, C. M. (2011).
Essentials of Pathophysiology: Concepts
of Altered Health States
(3rd edn). Philadelphia: Lippincott
Williams & Wilkins.
Porth, C. M. (2009).
Pathophysiology: Concepts of Altered Health
States
(8th edn). Philadelphia: Lippincott Williams & Wilkins.
Reddel, H. (2012). Rational prescribing for ongoing management of
asthma in adults.
Australian Prescriber, 35(2),
43–46.
Sin, D. D., Man, J., Sharpe, H., Gan, W. Q. & Man, S. F. (2004).
Pharmacological management to reduce exacerbations in adults
with asthma: A systematic review and meta-analysis.
JAMA,
293
, 367–376.
Sutherland, R. E. & Cherniak, R. M. (2004). Management of
COPD.
New England Journal of Medicine, 350
, 2689–2697.
Van Asperen, P. (2012). Long-acting beta2 agonists for childhood
asthma.
Australian Prescriber, 35(4)
, 111–113.
Worsnop, C. (2005). Combination inhalers for asthma.
Australian
Prescriber
,
28
, 26–28.
C H E C K Y O U R U N D E R S T A N D I N G
Answers to the questions in this chapter can be found in
Appendix A at the back of this book.
MULTIPLE CHOICE
Select the best answer to the following.
1.
Treatment of obstructive pulmonary disorders is
aimed at:
a.
opening the conducting airways or decreasing the
effects of inflammation.
b.
blocking the autonomic reflexes that alter
respirations.
c.
blocking the effects of the immune and
inflammatory systems.
d.
altering the respiratory membrane to increase the
flow of oxygen and carbon dioxide.
2.
The xanthines:
a.
block the sympathetic nervous system.
b.
stimulate the sympathetic nervous system.
c.
directly affect the smooth muscles of the
respiratory tract.
d.
act in the CNS to cause bronchodilation.
3.
A person has been maintained on theophylline for
many years and has recently taken up smoking.
The theophylline levels in this person would be
expected to:
a.
rise, because nicotine prevents the breakdown of
theophylline.
b.
stay the same, because smoking has no effect on
theophylline.
c.
fall, because the nicotine stimulates liver
metabolism of theophylline.
d.
rapidly reach toxic levels.
4.
A person with hypertension and known heart
disease has frequent bronchospasms and
asthma attacks that are most responsive to
sympathomimetic drugs. This person might be best
treated with:
a.
an inhaled sympathomimetic to decrease systemic
effects.
b.
a xanthine.
c.
no sympathomimetics because they would be
contraindicated.
d.
an anticholinergic.
